Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Sequelae and Quality of Life in Patients Living at Home 1 Year After a Stroke Managed in Stroke Units.

Broussy S, Saillour-Glenisson F, García-Lorenzo B, Rouanet F, Lesaine E, Maugeais M, Aly F, Glize B, Salamon R, Sibon I.

Front Neurol. 2019 Aug 21;10:907. doi: 10.3389/fneur.2019.00907. eCollection 2019.

2.

Structural studies of the binding of an antagonistic cyclic peptide to the VEGFR1 domain 2.

Wang L, Coric P, Broussy S, Di Stasi R, Zhou L, D'Andrea LD, Ji L, Vidal M, Bouaziz S, Liu WQ.

Eur J Med Chem. 2019 May 1;169:65-75. doi: 10.1016/j.ejmech.2019.02.069. Epub 2019 Mar 1.

PMID:
30856407
3.

Post-stroke follow-up: Time to organize.

Santos E, Broussy S, Lesaine E, Saillour F, Rouanet F, Dehail P, Joseph PA, Aly F, Sibon I, Glize B.

Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):59-64. doi: 10.1016/j.neurol.2018.02.087. Epub 2018 Oct 4.

PMID:
30293879
4.

Colorimetric immunoassays for the screening and specificity evaluation of molecules disturbing VEGFs/VEGFRs interactions.

Trapiella-Alfonso L, Broussy S, Liu WQ, Vidal M, Lecarpentier E, Tsatsaris V, Gagey-Eilstein N.

Anal Biochem. 2018 Mar 1;544:114-120. doi: 10.1016/j.ab.2017.12.029. Epub 2017 Dec 25.

PMID:
29284120
5.

Synthesis and characterization of water-soluble macrocyclic peptides stabilizing protein α-turn.

Wang L, Coric P, Zhu K, Liu WQ, Vidal M, Bouaziz S, Broussy S.

Org Biomol Chem. 2018 Jan 17;16(3):459-471. doi: 10.1039/c7ob02852k.

PMID:
29265149
6.

Identification of Peptidic Antagonists of Vascular Endothelial Growth Factor Receptor 1 by Scanning the Binding Epitopes of Its Ligands.

Wang L, Zhou L, Reille-Seroussi M, Gagey-Eilstein N, Broussy S, Zhang T, Ji L, Vidal M, Liu WQ.

J Med Chem. 2017 Aug 10;60(15):6598-6606. doi: 10.1021/acs.jmedchem.7b00283. Epub 2017 Jul 21.

PMID:
28686443
7.

VEGFR1 domain 2 covalent labeling with horseradish peroxidase: Development of a displacement assay on VEGF.

Reille-Seroussi M, Gaucher JF, Cussac LA, Broutin I, Vidal M, Broussy S.

Anal Biochem. 2017 Aug 1;530:107-112. doi: 10.1016/j.ab.2017.05.004. Epub 2017 May 3.

PMID:
28477965
8.

Biophysical Studies of the Induced Dimerization of Human VEGF Receptor 1 Binding Domain by Divalent Metals Competing with VEGF-A.

Gaucher JF, Reille-Seroussi M, Gagey-Eilstein N, Broussy S, Coric P, Seijo B, Lascombe MB, Gautier B, Liu WQ, Huguenot F, Inguimbert N, Bouaziz S, Vidal M, Broutin I.

PLoS One. 2016 Dec 12;11(12):e0167755. doi: 10.1371/journal.pone.0167755. eCollection 2016.

9.

Guttiferone A Aggregates Modulate Silent Information Regulator 1 (SIRT1) Activity.

Cottet K, Xu B, Coric P, Bouaziz S, Michel S, Vidal M, Lallemand MC, Broussy S.

J Med Chem. 2016 Oct 27;59(20):9560-9566. Epub 2016 Oct 7.

PMID:
27669815
10.

Mini-ISES identifies promising carbafructopyranose-based salens for asymmetric catalysis: Tuning ligand shape via the anomeric effect.

Karukurichi KR, Fei X, Swyka RA, Broussy S, Shen W, Dey S, Roy SK, Berkowitz DB.

Sci Adv. 2015 Jul;1(6). pii: e1500066. Epub 2015 Jul 10.

11.

Vascular Endothelial Growth Factor Peptide Ligands Explored by Competition Assay and Isothermal Titration Calorimetry.

Reille-Seroussi M, Gaucher JF, Desole C, Gagey-Eilstein N, Brachet F, Broutin I, Vidal M, Broussy S.

Biochemistry. 2015 Aug 25;54(33):5147-56. doi: 10.1021/acs.biochem.5b00722. Epub 2015 Aug 13.

PMID:
26222917
12.

[Seasonal influenza vaccination coverage of general practitioners and their patients. Practice survey of French general practitioners after vaccination campaign 2011-2012].

Joseph JP, Staffolani F, Kinouani S, Broussy S, Picat MQ, Senand B, Ducos G.

Rev Epidemiol Sante Publique. 2014 Oct;62(5):291-6. doi: 10.1016/j.respe.2014.07.003. Epub 2014 Oct 16. French.

PMID:
25444836
13.

Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists.

Wang L, Gagey-Eilstein N, Broussy S, Reille-Seroussi M, Huguenot F, Vidal M, Liu WQ.

Molecules. 2014 Sep 26;19(10):15391-407. doi: 10.3390/molecules191015391.

14.

Combinatorial catalysis employing a visible enzymatic beacon in real time: synthetically versatile (pseudo)halometalation/carbocyclizations.

Friest JA, Broussy S, Chung WJ, Berkowitz DB.

Angew Chem Int Ed Engl. 2011 Sep 12;50(38):8895-9. doi: 10.1002/anie.201103365. Epub 2011 Aug 16. No abstract available.

15.

Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens.

Friest JA, Maezato Y, Broussy S, Blum P, Berkowitz DB.

J Am Chem Soc. 2010 May 5;132(17):5930-1. doi: 10.1021/ja910778p.

16.

Enantioselective, ketoreductase-based entry into pharmaceutical building blocks: ethanol as tunable nicotinamide reductant.

Broussy S, Cheloha RW, Berkowitz DB.

Org Lett. 2009 Jan 15;11(2):305-8. doi: 10.1021/ol802464g.

17.

Solid phase synthesis of highly substituted tetrahydropyrans by tandem ene-reaction/intramolecular Sakurai cyclization.

Broussy S, Waldmann H.

J Comb Chem. 2007 Nov-Dec;9(6):1138-43. Epub 2007 Oct 13.

PMID:
17935301
18.

The first chemical synthesis of the core structure of the benzoylhydrazine-NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase.

Broussy S, Bernardes-Génisson V, Quémard A, Meunier B, Bernadou J.

J Org Chem. 2005 Dec 9;70(25):10502-10.

PMID:
16323864
19.

Guanine oxidation by electron transfer: one- versus two-electron oxidation mechanism.

Kupan A, Saulière A, Broussy S, Seguy C, Pratviel G, Meunier B.

Chembiochem. 2006 Jan;7(1):125-33.

PMID:
16323222
20.

1H and 13C NMR characterization of pyridinium-type isoniazid-NAD adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis.

Broussy S, Bernardes-Génisson V, Coppel Y, Quémard A, Bernadou J, Meunier B.

Org Biomol Chem. 2005 Feb 21;3(4):670-3. Epub 2005 Jan 21.

PMID:
15703806
21.

Studies on the 4-benzoylpyridine-3-carboxamide entity as a fragment model of the Isoniazid-NAD adduct.

Broussy S, Bernardes-Génisson V, Gornitzka H, Bernadou J, Meunier B.

Org Biomol Chem. 2005 Feb 21;3(4):666-9. Epub 2005 Jan 13.

PMID:
15703805
22.
23.

Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.

Nguyen M, Quémard A, Broussy S, Bernadou J, Meunier B.

Antimicrob Agents Chemother. 2002 Jul;46(7):2137-44.

Supplemental Content

Loading ...
Support Center